Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 6/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8863111 | 0.87 | NPSR1 (0.55) | SMN1; SMN2ALDH1A1POLBTNFPDE4A | |
| SCHEMBL7994728 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1POLBLMNAMAPT | |
| SCHEMBL27827515 | 0.81 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1HPGDLMNANPC1 | |
| SCHEMBL7876188 | 0.80 | POLB (0.58) | SMN1; SMN2HPGDPOLBTNFPDE4A | |
| SCHEMBL4671897 | 0.80 | ACHE (0.59) | SMN1; SMN2ALDH1A1POLBACHETNF | |
| SCHEMBL30540379 | 0.80 | ACHE (0.59) | SMN1; SMN2ALDH1A1POLBACHETNF | |
| SCHEMBL2991798 | 0.80 | ACHE (0.59) | SMN1; SMN2ALDH1A1POLBACHETNF | |
| SCHEMBL5720955 | 0.80 | ACHE (0.59) | SMN1; SMN2ALDH1A1POLBACHETNF | |
| SCHEMBL5941271 | 0.78 | TNF (0.55) | ALDH1A1POLBACHETNFPDE4A | |
| SCHEMBL6251186 | 0.78 | TNF (0.55) | ALDH1A1POLBACHETNFPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION | 2018-11-08 | — | — | US | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | NEW YORK UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| EP-3142663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | CELGENE CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3065778-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | Celgene Corporation (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9408831-B2 | Methods for treating respiratory viral infection | CELGENE CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-6284780-B1 | PREVENT TUMOR NECROSIS FACTOR RETROVIRUS REPRODUCTION | CELGENE CORPORATION | 2001-09-04 | — | — | US | disclosed |
| WO-2001043743-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS, RESTENOSIS AND RELATED DISORDERS | CELGENE CORP. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6180355-B1 | Method for diagnosing and treating chronic pelvic pain syndrome | UNIVERSITY OF MARYLAND, BALTIMORE | 2001-01-30 | — | — | US | disclosed |
| US-6046221-A | USEFUL FOR REDUCING LEVELS OF TUMOR NECROSIS FACTOR-ALPHA IN A MAMMAL | CELGENE CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0800505-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0800505-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020915-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020915-A1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289188-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE4C | SMN1; SMN2 630/4885ALDH1A1 1974/4885HPGD 673/4885 |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE3B | SMN1; SMN2 3415/4885ALDH1A1 1187/4885HPGD 288/4885 |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | PDE4A, PDE4B, PDE3A | SMN1; SMN2 2595/4885ALDH1A1 2091/4885HPGD 245/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | SMN1; SMN2 2595/4885ALDH1A1 2091/4885HPGD 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.